Skip to main content
Ashleigh Kimberlin and Mikayla Molnar achieve success with a gas-trapping apparatus for Ac-225 production. Credit: ORNL, U.S. Dept. of Energy

In experiment after experiment, the synthetic radioisotope actinium-225 has shown promise for targeting and attacking certain types of cancer cells.

ORNL researchers produced self-healable and highly adhesive elastomers, proving they self-repair in ambient conditions and underwater. This project garnered a 2021 R&D 100 Award. Credit: ORNL, U.S. Dept. of Energy

Research teams from the Department of Energy’s Oak Ridge National Laboratory and their technologies have received seven 2021 R&D 100 Awards, plus special recognition for a COVID-19-related project.

ORNL’s Christine Walker, a technical consultant and researcher in the Integrated Building Performance Group, works with the nation’s federally owned buildings through the Federal Energy Management Program, helping to reduce their carbon footprint and improve their energy performance. Credit: ORNL/U.S. Dept. of Energy

She may not wear a white coat or carry a stethoscope, but Christine Walker of ORNL spends her days diagnosing the energy health of buildings and figuring out how to improve their efficiency to achieve cost savings and reduce their carbon footprint.

Former ORNL Director Thom Mason presents Tom Kollie with a National Intelligence Meritorious Unit Citation on behalf of James Clapper, former director of national intelligence, and the national intelligence community in June 2017. Credit: Jason Richards/ORNL, U.S. Dept. of Energy

A 25-year career with the U.S. Navy, commanding combat missions overseas, brought Tom Kollie back to where he came from — ready to serve his country in a new way.

 

A new tool that simulates the energy profile of every building in America will give homeowners, utilities and companies a quick way to determine energy use and cost-effective retrofits that can reduce energy and carbon emissions.

A new tool that simulates the energy profile of every building in America will give homeowners, utilities and companies a quick way to determine energy use and cost-effective retrofits that can reduce energy and carbon emissions.

ORNL’s Jason DeGraw, a mechanical engineer and indoor air quality expert, uses numerical equations powered by high-performance computing to analyze and solve problems related to the dispersion patterns of biological pathogens as well as chemical irritants in buildings. Credit: ORNL, U.S. Dept. of Energy

Long before COVID-19’s rapid transmission led to a worldwide pandemic, Oak Ridge National Laboratory’s Jason DeGraw was performing computer modeling to better understand the impact of virus-laden droplets on indoor air quality

Innovation Crossroads Cohort 5 includes left to right: Caleb Alexander, DayLyte Batteries; Sam Evans, Unbound Water Technologies; Tommy Gibbons, Hempitecture; Shuchi “SK” Khurana, Addiguru; Forrest Shriver, Sentinel Devices; and Philip Stuckey, FC Renew.

Six science and technology innovators from across the United States will join the fifth cohort of Oak Ridge National Laboratory’s Innovation Crossroads program in June.

Balendra Sutharshan

In the mid-1980s, Balendra Sutharshan moved to Canada from the island nation of Sri Lanka. That move set Sutharshan on a path that had him heading continent-spanning collaborations and holding leadership posts at multiple Department of Energy

Brenda Smith, shown here working with a gas viscometer in her research lab, is one of several people concurrently researching the thermophysical properties of feedstock gas. Their research will support computational researchers who are designing processes to separate isotopes. Credit: Carlos Jones/ORNL, US Dept. of Energy

For years Brenda Smith found fulfillment working with nuclear batteries, a topic she’s been researching as a chemist at Oak Ridge National Laboratory.

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.